Lunai Bioworks Inc. (2Q5)

Overview

Renovaro Inc. is a pioneering pre-clinical stage biotechnology entity focused on the development of novel pharmaceutical and biological therapies aimed at the treatment of critical illnesses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), and various forms of cancer within the United States. Formerly known as Renovaro Biosciences Inc., the company underwent a rebranding in February 2024, marking a significant milestone in its evolution. Positioned strategically in Los Angeles, California, Renovaro Inc. collaborates closely with leading institutions such as the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross to leverage groundbreaking scientific research and development initiatives.

Products and Services

• RENB-HV-01

An autologous HIV curative treatment in development that aims to provide a personalized approach to HIV eradication, leveraging the patient's own cells to combat the virus.

• RENB-HV-12

A therapeutic HIV vaccine designed to elicit a robust immune response against the HIV virus, potentially altering the course of treatment for those living with this chronic condition.

• RENB-HB-01

A gene therapy curative treatment targeting the hepatitis B virus, employing advanced gene-editing techniques to potentially cure HBV at the genetic level.

• RENB-DC-11

An allogeneic dendritic cell therapeutic vaccine for pancreatic cancer, this product focuses on stimulating the immune system to recognize and destroy pancreatic cancer cells.

• RENB-DC-12-XX

Similar to RENB-DC-11, this allogeneic dendritic cell therapeutic vaccine targets other solid tumors, offering hope for the treatment of various types of cancer with a single approach.

• RENB-HV-21

A sophisticated treatment combining allogeneic natural killer (NK) and gamma delta T-cells to target HIV, this product represents an innovative approach to enhancing the body's natural defense mechanisms against the virus.